Sinopharm Accord, Sinopharm Group unit, posts H1 net profit attributable to shareholders down 8.97% to RMB 606.2 millionPUBT·Aug 28 at 09:44 AM000028+0.74%200028+0.50%
Sinopharm sells 30.13% stake in Guorui Pharma to Shanghai Shyndec for RMB 240.07 millionPUBT·Aug 19 at 02:00 PM01099+0.89%000028+0.74%
Sinopharm Accord, Sinopharm Group subsidiary, posts H1 net profit RMB 606 million, down 8.97%PUBT·Aug 17 at 12:57 PM000028+0.74%200028+0.50%
HBM Holdings enters strategic biologics R&D collaboration with SinopharmPUBT·Jul 27 at 09:00 AM01099+0.89%02142-1.63%
Sinopharm declares final dividend of RMB 0.69 a share for FY2025PUBT·Jun 18 at 09:05 AM01099+0.89%000028+0.74%
Sinopharm Accord's Wind ESG rating has been upgraded to A, with a comprehensive score of 7.18, leading the ratings in the healthcare providers and services industry同壁财经·Jun 9 at 09:15 AM000028+0.74%
Sinopharm Seeks Shareholder Mandate for Up to 10% H-Share BuybackTip Ranks·May 27 at 10:57 PM600511-0.63%01099+0.89%
CICC Keeps Their Buy Rating on Sinopharm Group Co (SHTDF)Tip Ranks·Apr 28 at 06:58 AM01099+0.89%000028+0.74%
CLSA Raises Sinopharm TP to HKD25, Maintains OutperformAASTOCKS News·Apr 28 at 03:58 AM000028+0.74%01099+0.89%
Sinopharm Sets April Board Meeting to Approve First-Quarter 2026 ResultsTip Ranks·Apr 10 at 09:10 AM000028+0.74%600511-0.63%
Sinopharm Group Co (SHTDF) Gets a Buy from First Shanghai SecuritiesTip Ranks·Apr 5 at 05:16 AM01099+0.89%159849-0.20%
SINOPHARM stated that there are no plans for large-scale store closures this year, as health consumption has become a necessityStheadline·Mar 23 at 06:37 AM600511-0.63%000028+0.74%
Sinopharm Defies Industry Headwinds With 2025 Profit Growth and Retail TurnaroundTip Ranks·Mar 22 at 10:37 PM000028+0.74%600511-0.63%
Sinopharm Proposes Final Cash Dividend of RMB 0.69 per Share for 2025Tip Ranks·Mar 22 at 10:37 PM000028+0.74%01069-6.92%
SINOPHARM's subsidiary SINOPHARM(CNCM LTD) earned 1.997 billion RMB for the year, a slight decrease of 0.2%AASTOCKS·Mar 19 at 04:04 PM000028+0.74%588250-0.78%
